20.07.2012 - Sygnis Pharma is acquiring Spanish sequencing technology specialist X-Pol Biotech S.L., a subsidiary of Genetrix Life Sciences A.B. The German biotech said the move is a step forward into the molecular diagnostics business.
Under terms of the proposed deal Sygnis will take 100% ownership of X-Pol through a capital increase against contribution in kind. Once the transaction has been completed, existing X-Pol shareholders will hold 77.5% of all shares in Sygnis. The proposed terms of the deal have been approved by both firms’ executive and supervisory boards.
Madrid-based X-Pol was founded in 2008 to develop tools and technologies for DNA amplification and sequencing. Currently 84% owned by biotech incubator Genetrix. The lead product, Qualiphi polymerase, was recently licensed to Qiagen. X-Pol claims its DNA polymerases demonstrate unique properties that boost the performance of DNA amplification, and can be applied for a wide range of applications in DNA amplification, repair, sequencing, and genetic modification.
Sygnis said the acquisition of X-Pol will represent a major shift in its business focus. To date, the firm has specialised in the development of therapies for central nervous system disorders. Its pipeline was headed by a granulocyte colony–stimulating factor candidate filgrastim (AX200), which was evaluated in a Phase II trial as a treatment for ischemic stroke. However, the study data, reported in December 2011, failed to show any benefits of therapy using AX200. Sygnis confirmed in February that it was looking at M&A opportunities or other financing options. The Heidelberg-based firm said the aim will be to build the X-Pol DNA sequencing business and related activities within the field of molecular diagnostics. “The company will have an entirely new focus and business and will provide a lower risk profile with the near-term visibility of revenues and profitability”, Sygnis-CFO Peter Willinger said.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.